JP2024517318A5 - - Google Patents
Info
- Publication number
- JP2024517318A5 JP2024517318A5 JP2023569885A JP2023569885A JP2024517318A5 JP 2024517318 A5 JP2024517318 A5 JP 2024517318A5 JP 2023569885 A JP2023569885 A JP 2023569885A JP 2023569885 A JP2023569885 A JP 2023569885A JP 2024517318 A5 JP2024517318 A5 JP 2024517318A5
- Authority
- JP
- Japan
- Prior art keywords
- count
- lowest point
- pharmaceutical composition
- baseline
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| US63/201,749 | 2021-05-11 | ||
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517318A JP2024517318A (ja) | 2024-04-19 |
| JP2024517318A5 true JP2024517318A5 (https=) | 2025-05-16 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569885A Pending JP2024517318A (ja) | 2021-05-11 | 2022-05-10 | アザシチジンと組み合わせて骨髄異形成症候群の処置に使用されるベネトクラクス投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (https=) |
| EP (1) | EP4337183A4 (https=) |
| JP (1) | JP2024517318A (https=) |
| KR (1) | KR20240006659A (https=) |
| CN (1) | CN117642161A (https=) |
| AU (1) | AU2022273023A1 (https=) |
| BR (1) | BR112023023677A2 (https=) |
| CA (1) | CA3219760A1 (https=) |
| IL (1) | IL308321A (https=) |
| MX (1) | MX2023013364A (https=) |
| WO (1) | WO2022240786A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| KR20220004669A (ko) * | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
| JP2022537551A (ja) * | 2019-06-20 | 2022-08-26 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
-
2022
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101600438B (zh) | 疼痛疾病治疗剂 | |
| TRABER et al. | Vancomycin ototoxicity in a patient with normal renal function | |
| JP2022525149A5 (https=) | ||
| EP0585705B1 (en) | Use of monoclonal antibodies to TNF to treat bacterial meningitis | |
| Thodis et al. | Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis | |
| CA2513567A1 (en) | Cop 1 for treatment of inflammatory bowel diseases | |
| Engqvist et al. | Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study | |
| JP2024517318A5 (https=) | ||
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| EP0630649A1 (en) | Combination of an inhibitor of inducible nitric oxide synthase (iNOS) and an antiinflammatory agent, e.g. a corticosteroid | |
| CA2721728A1 (en) | Treatment of inflammatory bowel disease with 6-mercaptopurine | |
| Cocchi | Cortisone and corticotropin in the treatment of tuberculosis in infancy and childhood | |
| JPH1017478A (ja) | 潰瘍性大腸炎の予防又は治療剤 | |
| KR20220162821A (ko) | 스테로이드에 대한 내성을 극복하기 위한 글루타르이미드 유도체 | |
| JP2005529152A5 (https=) | ||
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| RU2023129202A (ru) | Режимы дозировки венетоклакса для применения в лечении миелодиспластических синдромов в сочетании с азацитидином | |
| EP2145624A1 (en) | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment | |
| Calle et al. | Nimodipine has no beneficial effect on neurological outcome in a cardiopulmonary arrest model in the rat | |
| RU2071773C1 (ru) | Лекарственное средство для лечения синдромов приобретенного иммунодефицита, в том числе вич-обусловленных | |
| CN116549428B (zh) | 4-羟基异亮氨酸的新用途 | |
| JP4627580B2 (ja) | 肝疾患処置剤 | |
| Török et al. | Comparative study of a long-acting quinidine preparation and quinidine sulphate in chronic atrial fibrillation | |
| Assali | Renal effects of hydrochlorothiazide in normal and toxemic pregnancy | |
| Riedl et al. | Hereditary Angioedema Disease Control After Switching To Donidalorsen From Prior Long-Term Prophylaxis: Results From The OASISplus Open-Label Extension Study |